LG Chem will decide within the month if it will take over Nissan’s factory in Barcelona and turn it into a battery plant.
Since LG Chem is expected to employ 1,500 in the plant, the deal would allow all Nissan factory workers to keep their jobs.
The Spanish government has proposed direct aid of $711 million out of the $1.88 billion required for the acquisition of the plant, which is scheduled for closure in December 2021.
LG Chem is set to notify the Spanish government about its decision within this month.
If the deal pushes through, Spain will become LG Chem’s second electric vehicle (EV) battery production in Europe, after Poland.
Spain is the No. 2 EV manufacturing country in Europe after Germany.
An LG Chem official said their company is one of two candidates for the acquisition.


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Instagram Outage Disrupts Thousands of U.S. Users
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



